Sandostatin - Octreotide acetate

Octreotide acetate (Sandostatin) is a synthetic peptide analogue of the hormone somatostatin. Its actions include inhibition of the pituitary secretion of growth hormone and an inhibition of pancreatic islet cell secretion of insulin and glucagon. Unlike somatostatin, which has a plasma half-life of a few minutes, octreotide has a plasma elimination half-Hfe of 1 to 2 hours. Excretion of the drug is primarily renal. 

Recommended dosage and monitoring requirements Sandostatin injectable solution is usually administered subcutaneously in initial doses of 50 to 100 pg two or three times daily. Upward dose titration is frequently required. Sandostatin LAR Depot injectable suspension should never be administered intravenously or subcutaneously. Patients not currently receiving octreotide acetate should begin therapy with subcutaneous injections and then can be switched to the depot injection of 20mg intragluteally at 4-week intervals for 3 months. 

Lau, D.T.W., et al. 1994. Effect of current magnitude and drug concentration on iontophoretic delivery of octreotide acetate (Sandostatin ) in the rabbit. Pharm Res 11 1742. 

Octreotide acetate injectable suspension (octreotide long-acting release Sandostatin LAR) is a slow-release formulation in which octreotide is incorporated into microspheres. It is instituted only after a brief course of shorter-acting octreotide has been demonstrated to be effective and tolerated. The microspheres must be carefully put into suspension and immediately injected into a gluteal muscle. Injections into alternate gluteal muscles are repeated at 4-week intervals in doses of 20-40 mg. Octreotide is extremely costly. 

Octreotide acetate 84-(Sandostatin) SC/IM/IV after dilution Lactic acid 0.34% pH 4.2... 

A powerful new synthetic peptide that mimics the action of somatostatin, octreotide acetate (Sandostatin). is approved by the Food and Drug Administration (FDA) for (he treatment of certain rare forms of intestinal endocrine cancers, such as malignant carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). Octreotide acetate is indicated for long-term treatment of severe diarrhea associated with these carcinomas. 

Octreotide acetate (Sandostatin) 1.02 13.6L 1.7-1.9 SC (1.0) IM (0.60-0.63) Severe diarrhea caused by carcinoid tumors or tumors secreting vasoactive intestinal peptide acromegaly... 

Sandostatin LAR Octreotide acetate Novartis Acromegaly SC/IM Marketed... 

---